Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1645 1649 1651 1674 1675 1677 1678
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18691254 | CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | Non-Final OA | Janssen Biotech, Inc. |
| 18289568 | ANTIBODIES AGAINST ALK AND METHODS OF USE THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18528645 | SYSTEMS AND METHODS FOR THE PREPARATION OF PEPTIDE-MHC-I COMPLEXES WITH NATIVE GLYCAN MODIFICATIONS | Non-Final OA | The Regents of The University of California |
| 18230480 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Final Rejection | The Regents of the University of California |
| 17799444 | PLATELET FACTORS AND COGNITIVE IMPROVEMENT | Non-Final OA | The Regents of the University of California |
| 18559732 | REGULATING T CELL IMMUNE RESPONSE THROUGH IGF-I RECEPTOR (IGF-1R) | Non-Final OA | The Regents of the University of Michigan |
| 18487767 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AUTOIMMUNE INDUCED CARDIAC LONG QT SYNDROME | Final Rejection | New York University |
| 18581931 | AUTOIMMUNE ANTIBODIES FOR USE IN INHIBITING CANCER CELL GROWTH | Non-Final OA | The Johns Hopkins University |
| 17623913 | ANTIBODY DRUG CONJUGATE PURIFICATION | Non-Final OA | Merck Patent GmbH |
| 18021085 | IGFBP7 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18363136 | HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 | Non-Final OA | BioNTech SE |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy